Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27432299 | 0.87 | CYP3A4 (0.66) | CYP3A4SLC7A5NLN | |
| SCHEMBL18862447 | 0.87 | CYP3A4 (0.61) | CYP3A4SLC7A5NLN | |
| SCHEMBL19227330 | 0.83 | CYP3A4 (0.63) | CYP3A4SLC7A5NLN | |
| SCHEMBL12259752 | 0.83 | CYP3A4 (0.63) | CYP3A4SLC7A5NLN | |
| SCHEMBL29429285 | 0.83 | CYP3A4 (0.59) | CYP3A4SLC7A5NLN | |
| SCHEMBL18878637 | 0.82 | NLN (0.66) | CYP3A4SLC7A5NLN | |
| SCHEMBL6957266 | 0.81 | CYP3A4 (0.69) | CYP3A4SLC7A5NLN | |
| SCHEMBL13331622 | 0.81 | CYP3A4 (0.69) | CYP3A4SLC7A5NLN | |
| SCHEMBL27946609 | 0.81 | CYP3A4 (0.69) | CYP3A4SLC7A5NLN | |
| SCHEMBL18162790 | 0.81 | CYP3A4 (0.69) | CYP3A4SLC7A5NLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946074-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2021-03-16 | — | — | US | disclosed |
| US-20190038721-A1 | GLP-1 DERIVATIVES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038721-A1 | GLP-1 DERIVATIVES AND USES THEREOF | GLP1R, DPP8, DPP7 | CYP3A4 1346/4885SLC7A5 930/4885NLN 1898/4885 |
| US-10946074-B2 | GLP-1 derivatives and uses thereof | GLP1R, DPP8, DPP7 | CYP3A4 1346/4885SLC7A5 930/4885NLN 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.